Interestingly, the expression of ZNF683 in CD8+ T cells, a pivotal regulator of T cell activation and cytotoxicity, has been reported to correlate with a better response to anti‐PD‐1 therapy in patients with CLL and Richter Syndrome [21, 61]. This evidence concerns the gene PDCD1 and B-cell chronic lymphocytic leukemia.